GH secretagogues are an expanding class of synthetic peptide and nonpeptide molecules that stimulate the pituitary gland to secrete GH through their own specific receptor, the GH-secretagogue receptor. The cloning of the receptor for these nonclassical GH releasing molecules, together with the more recent characterization of an endogenous ligand, named ghrelin, have unambiguously demonstrated the existence of a physiological system that regulates GH secretion. Somatotroph cellspecific expression of the GH gene is dependent on a pituitary-specific transcription factor (Pit-1). This factor is transcribed in a highly restricted manner in the anterior pituitary gland. The present experiments sought to determine whether the synthetic hexapeptide GHRP-6, a reference GH secretagogue compound, as well as an endogenous ligand, ghrelin, regulate pit-1 expression. By a combination of Northern and Western blot analysis we found that GHRP-6 elicits a time-and dosedependent activation of pit-1 expression in monolayer cultures of infant rat anterior pituitary cells. This effect was blocked by pretreatment with actinomycin D, but not by cycloheximide, suggesting that this action was due to direct transcriptional activation of pit-1. Using an established cell line (HEK293-GHS-R) that overexpresses the GH secretagogue receptor, we showed a marked stimulatory effect of GHRP-6 on the pit-1 ؊2,500 bp 5-region driving luciferase expression. We truncated the responsive region to ؊231 bp, a sequence that contains two CREs, and found that both CREs are needed for GHRP-6-induced transcriptional activation in both HEK293-GHS-R cells and infant rat anterior pituitary primary cultures. The effect was dependent on PKC, MAPK kinase, and PKA activation. Increasing Pit-1 by coexpression of pCMV-pit-1 potentiated the GHRP-6 effect on the pit-1 promoter. Similarly, we showed that the endogenous GH secretagogue receptor ligand ghrelin exerts a similar effect on the pit-1 promoter. These data provide the first evidence that ghrelin, in addition to its previously reported GHreleasing activities, is also capable of regulating pit-1 transcription through the GH secretagogue receptor in the pituitary, thus giving new insights into the physiological role of the GH secretagogue receptor on somatotroph cell differentiation and function. (Molecular Endocrinology 15: 1484-1495,  2001 ) G H SECRETAGOGUES (GHS) are synthetic compounds developed to release GH in vitro (1). These compounds were predicted to mimic the effect of an endogenous factor that would activate a specific receptor in the pituitary and the hypothalamus (2-4). The cloning of the receptor for these nonclassical GH releasing compounds, together with the more recent characterization of endogenous ligands, ghrelin and des-Gln14-ghrelin (5, 6), have unambiguously demonstrated the existence of a physiological system that regulates GH secretion along with GHRH and somatostatin. Ghrelin and/or GHS administered alone or in combination with GHRH are potent and highly reproducible GH releasers in rats (7) and humans (8, 9) and are useful tools for the diagnosis of GH deficiency when tested in a variety of pathological conditions, both in children and in adults (10, 11). As therapeutic agents, they show clinical effectiveness in enhancing GH release. At present, they are being evaluated in long-term controlled clinical studies to assess their potential benefits in a variety of disease states such as idiopathic GH deficiency, catabolic states, obesity, osteoporosis, and heart failure (12). Furthermore, recent evidence indicates that by acting at a central level, ghrelin may play an important role in body weight homeostasis (13, 14) .
G H SECRETAGOGUES (GHS) are synthetic compounds developed to release GH in vitro
. These compounds were predicted to mimic the effect of an endogenous factor that would activate a specific receptor in the pituitary and the hypothalamus (2) (3) (4) . The cloning of the receptor for these nonclassical GH releasing compounds, together with the more recent characterization of endogenous ligands, ghrelin and des-Gln14-ghrelin (5, 6) , have unambiguously demonstrated the existence of a physiological system that regulates GH secretion along with GHRH and somatostatin. Ghrelin and/or GHS administered alone or in combination with GHRH are potent and highly reproducible GH releasers in rats (7) and humans (8, 9) and are useful tools for the diagnosis of GH deficiency when tested in a variety of pathological conditions, both in children and in adults (10, 11) . As therapeutic agents, they show clinical effectiveness in enhancing GH release. At present, they are being evaluated in long-term controlled clinical studies to assess their potential benefits in a variety of disease states such as idiopathic GH deficiency, catabolic states, obesity, osteoporosis, and heart failure (12) . Furthermore, recent evidence indicates that by acting at a central level, ghrelin may play an important role in body weight homeostasis (13, 14) .
The expression of the GH gene is restricted to somatotrophs and somatomammotrophs in the pituitary gland and is under complex transcriptional control. Pituitary-specific expression of the GH gene is dependent on a pituitary-specific transcription factor, GH factor-1, a homeodomain protein also known as pituitary-specific transcription factor-1 (Pit-1) (15, 16) . This factor is transcribed in a highly restricted manner in the anterior pituitary (AP) gland. Pit-1 transcription is con-trolled by at least three primary signals: a cAMPactivated transcription factor, CREB (15) (16) (17) , autoregulation by its own gene product (17, 18) , and developmentally scheduled transcriptional activation by one or more other pituitary-specific transcription factors (19) .
Data obtained using primary cultures of adult rat AP cells have shown that GHRH plays a stimulatory role on pit-1 mRNA levels while IGF-I exerts an inhibitory effect (20) . Somewhat surprisingly it was found that GHRP-6, a reference GHS compound, was shown to be devoid of any effect on pit-1 mRNA levels in this experimental model. In addition to its effects on the rate of GH gene transcription, Pit-1 also appears to be involved in somatotroph cell proliferation. Because the effect of GHRP-6 on GH secretion is more prominent in infant rats than in adult rats, we assessed the effect of GHRP-6 on pit-1 expression in a monolayer culture of infant rat AP cells. Furthermore, we also characterized the effects of GHRP-6 on the pit-1 promoter using a stable cell line that overexpresses the GH secretagogue receptor (GHS-R). Finally, during these experiments the isolation and characterization of an endogenous ligand for the GHS-R, called ghrelin, was described (5); therefore, we also evaluated the effects of ghrelin on the pit-1 promoter.
RESULTS

GHRP-6 Increases Pit-1 Expression in Pituitary Cells Derived from Infant Rats
We have previously shown the lack of an effect of GHRP-6 on pit-1 gene expression in cells cultured from adult male rat pituitary glands (20) . We hypothesized that cells cultured from infant rat pituitaries would be more responsive. To test this notion, we examined the effect of 10 Ϫ6 M GHRP-6 on Pit-1 protein levels in adenohypophyseal primary cultures of 2-wkold male rats. We performed immunoprecipitationWestern analysis because Pit-1 levels were too low for detection by direct Western blots (data not shown). A marked increase in Pit-1 protein expression was observed after 1 h of GHRP-6 treatment, which was maintained for up to 12 h (Fig. 1A) . As controls, we performed anti-GH and anti-PRL Western blots with the same lysates and found no significant differences. Because GHRH increases pit-1 expression, we decided to test whether pit-1 was also regulated by GHRP-6. Figure 1B shows the effect of a maximal dose of GHRP-6 on pit-1 mRNA levels. There is a marked increase in pit-1 expression 1-2 h after the addition of GHRP-6. The increase in pit-1 is dose dependent and 10 Ϫ10 M GHRP-6 (Fig. 1C) , a GHRP-6 dose that fails to stimulate GH secretion (21) (22) (23) , also has no effect on pit-1 expression. We detected a significant increase in GH secretion in our cultures after 4 h of treatment with 10
Ϫ6 M GHRP-6, without any effect on PRL secretion (Fig. 2) . The stimulatory effect of GHRP-6 on pit-1 appears to be mediated through the GHS-R because the effect is antagonized by (DLys 3 )-GHRP-6 (21) (Fig. 1D) . We tested the possibility that GHRP-6 mediated its activity at the transcriptional level. Pretreatment of the cells with cycloheximide not only increases the basal levels of pit-1 mRNA but potentiates the GHRP-6 effect (Fig. 3) . After pretreatment of the cells with actinomycin D (Fig. 3) , GHRP-6 is unable to induce pit-1 expression. Collectively, these results argue that induction of a protein intermediate is not needed for GHRP-6-mediated increases in pit-1 transcription. In contrast to the results with pit-1, cycloheximide suppresses the effect of GHRP-6 on GH and PRL expression (Fig. 3) . Actinomycin D prevents GHRP-6 induced increases in GH and PRL expression. These results are consistent with GHRP-6 induction of Pit-1 being at least partially required for increasing GH and PRL expression.
Identification of 5-Flanking Regions Necessary for GHRP-6 Induction of Pit-1 Expression
Pit-1 activates and maintains the transcription of GH, PRL, and ␤-TSH genes (24, 25) . In our studies we saw an increase in the GH and PRL gene expression after GHRP-6 treatment. This might be mediated by transcriptional activation of pit-1, although there was a consistent difference in the maximal effective doses for pit-1 (10 Ϫ6 M) vs. GH or PRL (10 Ϫ8 M) (see Fig. 1C ). To further study the activity of GHRP-6 on the pit-1 promoter we exploited a HEK-293 cell line that stably expresses the GHS-R (HEK293-GHS-R). This cell line was transfected with a Ϫ2,500-bp fragment from the pit-1 promoter cloned upstream of the luciferase reporter gene. There was a dose-response (Fig. 4A ) and time-dependent (Fig. 4B) effect of GHRP-6 on luciferase activity.
The 5Ј-flanking region of pit-1 contains multiple consensus sequences for known transcription factors (Fig. 5A) (15) (16) (17) (26) (27) (28) . We made progressive deletions of the 5Ј-region and studied the response to GHRP-6 in the HEK293-GHS-R. There were no significant differences between Ϫ2500pit1-luc,Ϫ959pit1-luc, Ϫ458pit1-luc, Ϫ378pit1-luc, and Ϫ231pit1-luc, but the response was lost when the Ϫ194pit1-luc and Ϫ92pit1-luc were tested (Fig. 5B) . These results implicate CRE elements in GHRP-6 mediated activation of the pit-1 promoter. There are two CRE elements, proximal (Ϫ157/Ϫ150) and distal (Ϫ200/Ϫ193), and we investigated whether both were needed for activation by GHRP-6. When Ϫ231 mutP-CREpit1-luc is used, where four bases of the proximal CRE are mutated, the response to GHRP-6 is completely abolished (Fig. 5C) . Similarly, using Ϫ231 mutD-CREpit1-luc, where four bases of the distal CRE are mutated, the response to GHRP-6 is also blocked (Fig. 5C) . These data clearly demonstrate the importance of the proximal and distal CREs for mediating the action of GHRP-6 action on the pit-1 promoter. To investigate the potential signif-icance of another important 5Ј-flanking region, the Pit-1 binding site, we cotransfected a Pit1 expression vector (pCMV-pit1) with p-231pit1-luc into the HEK293-GHS-R cells. In these transfected cells, pit-1 expression in response to GHRP-6 is potentiated by 40% (Fig. 5D) .
The experiments conducted with the HEK293-GHS-R cells were repeated in a more physiologically A, Immunoprecipitation-Western blot showing the GHRP-6 induction on the levels of Pit-1 starting after 1 h and lasting at least 12 h. Linear exposed autoradiographs from six different replicate experiments were quantified by densitometry and mean Ϯ SEM are shown in the bar graphs, * P Ͻ 0.05. As control, 25 g of total lysates were run on SDS-PAGE and treated with anti-GH and anti-PRL. There were no differences between lanes. B, Northern blot showing a transient increase in pit-1 mRNA expression after 0.5 h treatment with 10 Ϫ6 M GHRP-6. The levels increased between 1 to 2 h of treatment, and basal levels were restored after 4 h. Pit-1-enhanced expression was correlated with an increase in GH and PRL mRNA expression. 18S rRNA is shown as a loading control. Quantitation was done as in panel A. *, P Ͻ 0.05; **, P Ͻ 0.01. C, Dose-response effect of GHRP-6 on pit-1, GH, and PRL mRNA expression. Cell dishes were treated during 90 min with vehicle or different doses of GHRP-6. Quantitation was done as in panel A. *, P Ͻ 0.05; **, P Ͻ 0.01. D, The effect of GHRP-6 is specific since can be blocked by increasing amounts of the D-Lys 3 -GHRP-6 GHS-R antagonist. All treatments were maintained during 90 min with vehicle, GHRP-6, or different doses of the antagonist. Quantitation was done as in panel A. *, P Ͻ 0.05; **, P Ͻ 0.01. relevant setting by using primary cultures of AP cells. These AP cell cultures constitute a mixed population of pituitary cells, and of course we have no control over which cells express the transfected DNA. However, when double immunofluorescence is used to localize GHS-R ligand binding and to localize GH in the cultured AP cells, the results show that GHS-R ligand binding occurs exclusively in GH containing cells (2) . Therefore, GHS-R-mediated GHRP-6 activation of pit1-luc can only occur in somatotrophs or somatomammotrophs. In young rat AP cells transfected with p-231pit1-luc, GHRP-6 activates the pit1 promoter, and this induction is abolished if either of the CRE elements are mutated (Fig. 5E ). When adult rat pituitary-cultures are transfected, GHRP-6 is unable to stimulate the pit-1 promoter in spite of the positive response with the control additive, forskolin (Fig. 5E ).
Mechanism of Activation of pit-1 by GHRP-6
The G protein-coupled GHS-R transduces a signal leading to GH secretion through Ca 2ϩ /PKC (29) (30) (31) . By contrast, our data indicate an effect on the pit-1 promoter that is mediated by a sequence initially described as a binding motif for the CREB transcription factor, which is dependent on cAMP and PKA for activation (32) . However, later reports describe binding of activating protein-1 (AP-1) transcription factors to CREs (33) (34) (35) and that phosphorylation and activation of CREB is mediated not only through PKA, but also through calmodulin kinase, ERK, and p38 activation (reviewed in Ref. 36) .
To clarify the signal transduction pathway leading to activation of the pit-1 promoter by GHRP-6, we investigated the effects of different protein kinase inhibitors in cells transfected with both the long 5Ј-region, Ϫ2500pit1-luc, or the minimal responsive region Ϫ231pit1-luc. As shown in Fig. 6 , A and C, the PKC inhibitor GF109203X completely blocks the response to GHRP-6 without affecting forskolin induction of the pit-1 promoter in the HEK293-GHS-R cells. As control, we tested the specificity of the PKC inhibitor using 12-O-tetradecanoylphorbol 13-acetate (TPA) on the longer construct, because in contrast to Ϫ231pit1-luc, TPA activates Ϫ2500pit-1. Indeed, Fig. 6A shows that the response to TPA is blocked by GF109203X. The PKC inhibitor also abolishes the effect of GHRP-6 on the expression of pit-1 in primary pituitary cell cultures (Fig. 6B) . To determine whether the stimulatory effects of GHRP-6 on Ϫ231pit-1 required an active adenylate cyclase-PKA pathway, we tested whether H89, a known blocker of PKA, would affect activation of Ϫ231pit-1. In the presence of H89, both forskolin and GHRP-6 fail to stimulate Ϫ231pit-1; hence, PKA activity is required for the GHRP-6 response (Fig. 6C) . The MAPK pathway may also be involved in activation of CREB by forskolin (37, 38) . Therefore, we tested the effect of the MAPK kinase (MEK) inhibitor PD98059 on Ϫ231pit1-luc (Fig. 6C) . PD98059 reduces basal activity and inhibits GHRP-6 activation. The PI3K inhibitor, LY294002, in spite of significantly reducing the basal levels of transcription, has no effect on GHRP-6 stimulation of the pit-1 promoter.
Isolation of the first endogenous ligand, ghrelin, for the GHS-R was described while our experiments were in progress (5). We therefore wished to determine whether ghrelin had the same stimulatory effects on pit-1 expression as that of the synthetic ligand GHRP-6. It is evident from a comparison of Fig. 7A with Fig. 4A , that ghrelin and GHRP-6 have equivalent activity on Ϫ2500pit1-luc. Ghrelin and GHRP-6 also have similar activity on Ϫ231pit-luc (Fig. 7B) . In addition, mutation of any of the CRE elements or deletion of the distal CRE abolished the stimulatory effect of ghrelin (Fig. 7C) . 
DISCUSSION
The only known significant in vitro biological effect of GHRP-6 on the pituitary gland described to date is the immediate release of GH and in some cases release of small amounts of PRL (reviewed in Refs. 2, 6, and 7). We now demonstrate that GHRP-6 increases the cellular amount of the Pit-1 transcription factor in infantrat primary anterior pituitary (AP) cell cultures in a dose-and time-dependent fashion. The increase can be blocked by actinomycin D, but not by cycloheximide, which is consistent with a direct effect at the transcriptional level. The biological relevance is illustrated by experiments showing that the GHRP-6-induced increase in pit-1 mRNA in AP cells is associated with increasing amounts of Pit-1 protein. The results with the GHS-R antagonist, D-Lys 3 -GHRP-6, leads us to conclude the effect to be GHS-R mediated based on inhibition of the GHRP-6-induced increase in pit-1 mRNA. This result is particularly relevant because it has been suggested that the synthetic GHS could be acting on more than one receptor on the pituitary gland (39) . A similar dose-and time-dependent increase of luciferase activity was established when GHRP-6 was evaluated after transfection of Ϫ2500pit-1-luc into HEK293-GHS-R.
We investigated which elements in the 5Ј-region of the rat pit-1 are involved in GHRP-6 induction. The GHS-R signal transduction has been characterized as involving the phospholipase C/IP 3 /diacylglycerol (DAG)/PKC pathway (29) (30) (31) . As a result of sequential promoter deletion, we found that AP-1 response elements between Ϫ932 and Ϫ875 were not needed for pit-1 transcriptional induction by GHRP-6. The main 5Ј-flanking region needed for GHRP-6 activation was located around Ϫ200, which includes two CREs (26) (27) (28) . Deleting the distal CRE suppressed GHRP-6 activation, suggesting that the important element was located between Ϫ200 and Ϫ193. Furthermore, we could abolish the response by mutating the distal CRE. However, when we mutated the proximal CRE but maintained the distal CRE, the response was also suppressed. The known data on the pit-1 5Ј-region stressed the importance of another element, the Pit-1 binding site. Indeed, when we expressed Pit-1 in HEK293-GHS-R cells, the GHRP-6 stimulation was potentiated. This demonstrated that both elements cooperate in the promoter activity. The physiological relevance of the results obtained in the HEK-293 cells was confirmed by repeating the studies after transfection of the pit1-luc constructs into AP primary cultures. In AP cells from infant rats, GHRP-6 produced significant activation of luciferase activity, which was suppressed by mutation or deletion of either, or both, CREs. Curiously, GHRP-6 did not activate the pit-1 promoter in pituitary cells derived from adult rats (20) . However, this age-dependence is not unique, because there are other examples in physiology of age-dependent differential regulation, such as the up-regulation of ␤-adrenergic receptors in adult rats after denervation, which is absent in infant rats (40) . The pituitaries of neonatal rats are also more responsive to GHRP-6 stimulation of GH release than those of adult rats (23) , which might be explained by differences in receptor levels or by activation of different signal transduction pathways. For example, the concentration of GHRP-6 needed for inducing pit-1 in the AP cells is about 100-fold higher than in the HEK293-GHS-R cells. In the AP, the GHS-R concentration is approximately 100-fold lower than in the HEK293-GHS-R cells. In addition to differences in GHS-R concentrations, a developmentally regulated alteration in components of the GHS-R signal transduction pathway is an equally viable possibility for explaining the age-related differential response. For example, expression of different adenylate-cyclase isoforms and different activities of protein kinases have been described in the young vs. adult rat (41, 42) .
The CRE is known to bind dimeric phosphorylated CREB transcription factors as well as heterodimers from the AP-1 family of transcription factors (33) (34) (35) (36) . Although CREB was initially associated with cAMP-PKA signal transduction pathways, other pathways, such as CaM kinase, Ras-ERK, and p38, can also phosphorylate and activate CREB (reviewed in Ref. 43 ). AP-1 members are activated by a broad range of signal transduction pathways including PKC, Janus kinase-signal transducer and activator of transcription, ternary complex factor, and MAPKs (34) . We show that pit-1 activation is dependent on PKC both in the HEK293-GHS-R cell line and in pituitary cells, which is consistent with activation of the Gq PLC/ DAG/PKC pathway described previously (29) (30) (31) . PKC has been shown to activate ERK resulting in CREB phosphorylation (Refs. 37 and 44; reviewed in Ref. 43 ). Consistent with GHRP-6 activating pit-1 through this pathway, the effect of GHRP-6 is suppressed by the MAPK pathway inhibitor PD98059. However, blocking PKA also suppresses the GHRP-6 effect. Two possible explanations are that activation of PKA through PKC-stimulated ERK leads to CREB phosphorylation and CRE activation, or that independent activation of CREB occurs through PKA together with PKC induction of AP-1 transcription factors. Either or both pathways could act on the two CRE regions. PKA activation by Gq/DAG/PKC/Ca 2ϩ implies a specific adenylate cyclase subtype stimulated by PKC or CamK IV (45) . However, no cAMP increase has been observed after GHRP-6 treatment, at least not in a short-term study (22, 30, 31, 46) . Alternatively, basal cAMP production, which would be inhibited by H89, might play an important permissive role for GHRP-6 and ghrelin stimulation of pit-1 expression via the CRE. Extensive work will be needed to elucidate the intracellular protein cascades leading to activation of the pit-1 promoter. -1 (50 ng of pCMV-pit1) potentiates the GHRP-6 effect on the pit-1 promoter. E, Similar results as in panels B and C were obtained in infant rats AP cultures but not in adult rats. Progressive deletions of In summary, we show that GHRP-6 and ghrelin induce activation of pit-1 in AP cells from infant rats. This effect is exerted directly on the pit-1 promoter and appears to be developmentally regulated, because it cannot be demonstrated in pituitary cells isolated from adult rats. Furthermore, the demonstration that the endogenous peptide, ghrelin, exerts a similar effect to GHRP-6 on the pit-1 promoter through the same CREs reinforces the physiological relevance of our results. Finally, these data provide the first evidence that ghrelin, in addition to its previous reported GH-releasing activities and inducer of hypothalamic gene expression (47, 48) , also interacts with the GHS-R and activates gene transcription through the pit-1 promoter without requiring new protein synthesis. We have demonstrated a physiological effect of the ghrelin-GHS-R system in the regulation of somatotroph cell function, namely, activation of pit-1 expression. This observation provides a new insight into the molecular role of the GHS-R that has potential relevance to developmental biology.
MATERIALS AND METHODS
All culture media and restriction enzymes were obtained from Life Technologies, Inc. (Gaithersburg, MD). Tissue culture plasticware was from Nunc. GHRP-6 and ghrelin were obtained from Peninsula Laboratories, Inc. (Belmont, CA). (DLys 3 )-GHRP-6 was from Bachem (Torrance, CA). H89 and PD98059 were purchased from Calbiochem (La Jolla, CA). Cycloheximide, actinomycin D, GF109203X, LY294002, and all other reagents were obtained from Sigma (St. Louis, MO), unless otherwise specified. Random primed DNA labeling kit was from New England Biolabs, Inc. (Beverly, MA). Fugene was obtained from Roche Molecular Biochemicals (Indianapolis, IN) G418, Hybond-Nϩ nylon membranes, 125 I, ␣ 32 PdCTP, and ␥ 32 P-dATP were from Amersham Pharmacia Biotech (Arlington Heights, IL).
Culture Medium
Defined medium (serum-free) consisted of Ham's F12/ DMEM/BGjb medium in a ratio of 6:3:1 (vol/vol/vol) supplemented with: (per liter) BSA (2 g), HEPES (2.38 g), hydrocortisone (143 g), T 3 (0.4 g), transferrin (10 mg), glucagon (10 ng), epidermal growth factor (0.1 g), and fibroblast growth factor (0.2 g). Just before culturing the cells, the following were added: 2 mM glutamine, 100 IU/ml penicillin, 100 g/ml streptomycin, 2.5 g/ml amphotericin-B plus 2.5% FCS. The HEK293-GHS-R cell line was cultured in high-glucose DMEM plus 10% FCS, glutamine, and penicillin-streptomycin solution plus 500 g/ml G-418.
Cell Culture
Rat anterior pituitary cells were cultured as previously described (49) . Two-week-old (30-50 g) or adult (250 g) male Sprague Dawley rats were decapitated. The AP glands were removed, minced, and enzymatically dispersed using a solution of 0.4% (wt/vol) type IA collagenase, 0.2% (wt/vol) dispase, 0.1% (wt/vol) hyaluronidase, 0.01% (wt/vol) DNase I, and 10% (vol/vol) FCS in Earle's balanced salt solution (EBSS). The digest was placed in an incubator at 37 C for 1 h and mechanically dispersed at 15-min intervals. The dispersed cell suspension was centrifuged, and the pellet was washed with EBSS and finally resuspended in defined medium containing 2.5% FCS and antibiotics. Cells were plated and incubated at 37 C in a humidified atmosphere of 95% air-5% CO 2 for a period of 4 d.
RIAs
GH and PRL levels were measured in the culture medium with a RIA using the NIDDK standards (49) .
Immunoprecipitation and Western Blot Analysis
We used eight pituitaries per 60-mm dish. The day of the experiment all dishes were washed three times with EBSS, and serum-free defined medium was added. The cultures were treated progressively at the appropriate times, and 24 h later cells from all the dishes were harvested simultaneously. The dishes were washed three times in cold PBS, and cells were scraped in 100 l of hot 1% SDS and boiled for 5 min at 95 C. After addition of 900 l lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 5 mM EGTA, 1.5 mM MgCl 2 , 20 mM sodium pyrophosphate, 10 mM NaVO 4 , 4 mM PMSF, 50 g/ml aprotinin), lysates were sonicated briefly and microfuged for 5 min at 14,000 ϫ g at 4 C. Five hundred micrograms of total protein were immunoprecipitated overnight at 4 C with monoclonal anti-Pit-1 (Affinity Research, Mamhead, Exeter, UK). Thirty microliters of Gammabind (Amersham Pharmacia Biotech) were pipetted and end-to-end incubated during another 45 min. The beads were washed with HNTG buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100) and resuspended in 50 l of protein sample buffer. Samples were resolved on by 12% SDS-PAGE and electrotransferred onto a nitrocellulose membrane (Schleicher & Schuell, Inc., Keene, NH). Immunodetection was carried out as previously described (50) with a chemiluminescent system (Tropix, Inc., Bedford, MA) using a polyclonal anti-Pit-1 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at a dilution of 1:1000. For GH and PRL, 25 g of total cell lysates were loaded by 15% SDS-PAGE and transferred as before. Rabbit anti-GH and anti-PRL (NIDDK) were used at 1:5,000 dilution.
Northern Blot Analysis
Culture and treatment of the AP cultures were as in the Western blot except that 10 pituitaries per 60-mm dish were used. The protocol was previously described by Carneiro et al. (50) . Briefly, 10 g of total RNA (51) were run on a 1.5% formaldehyde agarose gel, stained with ethidium bromide, and transferred to a nylon membrane. Pit-1 (20) , GH (52) , and PRL (53) cDNA probes were labeled with a 32 P-dCTP. An oligonucleotide for the 18S RNA (ACGGTATCTGATCGTCT-TCGAACC) labeled with ␥ 32 P-dATP was used as an internal control to ensure equal loading among lanes. the 5Ј-region of pit-1 as well as CRE mutation constructs were cotransfected with ␤-gal in cultures of AP cells from infant or adult rats and incubated with vehicle, 10
Ϫ6 M GHRP-6 or 10 Ϫ5 M forskolin. The vehicle controls are all represented in a single 100% bar.
Transfections
HEK293-GHS-R is a cell line that stably expresses the human GHS-R [
35 S-MK0677 binding: B max ϭ 500 fmol/mg, dissociation constant (K d ) ϭ 0.5 nM (3)]. Forty thousand cells per well were seeded in 24-well dishes and allowed to attach overnight. Transfections were carried out in complete medium during 4 h using 3 l/well of Fugene and 1 g/well of total DNA, 0.7 g of the different pit-1 promoter-luc constructs, and 0.3 g rous sarcoma virus-␤-galactosidase (pRSV-␤-gal). After washing with EBSS, DMEM ϩ 0.1% BSA was added along with treatment for 24 h unless otherwise stated in the figure legends. Cells were lysed in 100 mM potassium phosphate, pH 7.8, 1 mM dithiothreitol by three freeze-thaw cycles. Luciferase activity was measured using a Nichols luminometer and ␤-galactosidase activity was measured at 420 nm using o-nitrophenyl-␤-D-galactopyranoside as substrate. For transfection of primary cultures, pituitaries were dispersed slightly differently than described above using collagenase type IV instead of type IA (54); 250,000 cells were allowed to attached overnight in defined medium plus 10% FCS. Transfections were carried out in serum-free medium during 4 h using 3 l/well of Fugene and 1 g/well of total DNA, 0.5 g of the different pit-1 promoter-luc constructs plus 0.5 g pRSV-␤-gal; 1% FCS was added for the next 2 h. Finally, the dishes were washed and various treatments were applied in serum-free defined medium.
Plasmids
Ϫ2500Pit1-luc was obtained by cloning the 5Ј-region of the pit-1 gene (55) on the NheI site of the pGL3 basic vector (Promega Corp., Madison, WI). The AccI/SmaI fragment was cloned on the same vector to obtain the Ϫ959pit1-luc, and sequentially, PvuII/SacI fragment originated Ϫ458pit1-luc, NsiI/SacI fragment gave Ϫ378pit1-luc, PleI/SmaI gave Ϫ231pit1-luc, AatII/SacI fragment gave Ϫ194Pit1-luc, and the HpaI/SmaI fragment gave Ϫ92pit1-luc. To obtain both CRE mutations, we used overlapping PCR using specific oligos. For Ϫ231 mutD-CRE-pit1-luc, upper fragment A: 5Ј-GTACCGAGCTCTTACGCGTGCTAGCC-3Ј and B: 5Ј-GAAACTTTATTTGGGCTCAGTAAGTGGG-3Ј giving a 74-pb product; lower fragment C: 5Ј-CCCACTTACTGAGCCCA-AATAAAGTTTC-3Ј and D: 5Ј-CCGGAATGCCAAGCTTACT-TAGATCG-3Ј giving a 250-bp product. For Ϫ231 mutP-CREpit1-luc, upper fragment A: 5Ј-GTACCGAGCTCTTACGC-GTGCTAGCC-3Ј and B: 5Ј-AACCTGGTTGTGGGCTATGA-AGTGAGGA-3Ј giving a 209-pb product; lower fragment C: 5Ј-TCCTCACTTCATAGCCCACAACCAGGTT-3Ј and D: 5Ј-CCGGAATGCCAAGCTTACTTAGATCG-3Ј giving a 118-bp product. The AB and CD products for each construct were combined and PCR-mix was added for 2 cycles (94 C, 30 sec; 37 C, 60 sec; 72 C, 5 min), followed by the addition of A and D primers and another 20 cycles (94 C, 45 sec; 48 C, 45 sec; 72 C, 1 min). Nhe/HindIII fragments were cloned in pGL3basic. The new constructs were sequenced using an ALF-express (Amersham Pharmacia Biotech).
Statistical Analysis
Data are expressed as mean Ϯ SEM. All the experiments were repeated at least three times in different weeks. For the transfections, each of the repeated experiments was done at least in triplicate per treatment. Transfection data are expressed as percentages over the basal transfected construct without treatment. Statistical analysis was carried out with the Mann-Whitney U test and the one-way ANOVA test. Significance is represented as follows: *, P Ͻ 0.05, ** P Ͻ 0.01. Fig. 4A . B, Ϫ231pit1-luc was transfected into HEK293-GHS-R cells and treated with increasing concentrations of ghrelin or GHRP-6 for 24 h. C, Effect of ghrelin on the pit-1 promoter is exerted in the same CRE region as GHRP-6, because deletion and mutation of either the distal or proximal CRE elements on the promoter abolishes the stimulatory effect of ghrelin. This figure should be compared with Fig. 5C .
